MedTrace Logo

Study of DM-101PX in Adults With Birch Pollen Allergy

NCT07254871 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-04-28

No results posted yet for this study

Summary

Randomized, double-blind placebo-controlled phase 2 trial with the aim to investigate safety and efficacy of DM-101-PX in reducing allergic symptoms provoked by nasal allergen challenge in birch pollen allergic adults. Expanded access to the study treatment is not available.

Conditions

  • Birch Pollen Allergy

Interventions

BIOLOGICAL

DM-101PX

subcutaneous injection of DM-101PX

BIOLOGICAL

Placebo

Placebo to match DM-101PX administered subcutaneously

Sponsors & Collaborators

  • Desentum Oy

    lead INDUSTRY

Principal Investigators

  • Dirk-Jan Opstelten, PhD · Desentum Oy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-26
Primary Completion
2026-04-15
Completion
2026-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07254871 on ClinicalTrials.gov